← 產業報告目錄

Clinical Trial Supplies Market by Services (Manufacturing, Sourcing, Packaging, Labelling, Logistics), Phases, Type (Small Molecules, Biologics, Vaccines), Therapeutic Areas (Oncology, Neurology, CVD, Ophthalmology, Dermatology) - Global Forecast to 2030

出版商 MarketsandMarkets產業別 Healthcare & Life Sciences出版日期 2025-03-31頁數 415報告編號 PH3772

授權報價

Single User Licence$4,950 USD
Multi User Licence$6,650 USD
Corporate User Licence$8,150 USD
Global User Licence$10,000 USD
洽詢購買 申請 Sample

報告摘要

The global Clinical Trial Supplies market is anticipated to reach USD 8.18 billion in 2030 from USD 5.34 billion in 2025, with a significant CAGR of 8.9%. The clinical trial supplies market is driven by the increasing volume and complexity of global clinical trials, the rise of personalized medicine, and stringent regulatory requirements. Decentralized and adaptive trial designs are fueling demand for specialized supply chain solutions, including direct-to-patient logistics and just-in-time inventory management. Growing biologics and cell & gene therapy trials necessitate temperature-controlled storage and distribution. Digitalization, such as IoT-enabled tracking and AI-driven demand forecasting, is optimizing supply chain efficiency. “Logistics & Distribution Services dominated the service segment” Based on services the market is segmented into Logistics & distribution, storage & retention, packaging, labeling and blinding, manufacturing, comparator sourcing and other services. Logistics & Distribution Services dominated the market in 2024 and Sourcing & Procurement Services is anticipated to grow at higher CAGR owing to increasing complexity of trial protocols, the globalization of clinical studies, and the rising demand for cost-effective supply chain management. Sponsors and CROs are outsourcing procurement to specialized vendors to ensure regulatory compliance, mitigate supply risks, and optimize inventory management. “Phase III segment dominate the phase segment in 2024” The phase segment is further divided into Phase I, Phase II, Phase III, Phase IV and Phase BA/BE. The rise of biologics, cell & gene therapies, and personalized medicine has further intensified the demand for specialized storage and transportation solutions in Phase III trials. The Phase II segment is anticipated to grow at a significant CAGR during the forecast period in the Clinical Trial Supplies Market owing to the rising focus on innovative therapies, including biologics, gene therapies, and targeted drugs, has led to a surge in Phase II trials, which assess the efficacy and optimal dosing of investigational treatments. “Pharmaceutical & Biotechnology Companies dominated the segment” Based on the end users, the market is segmented into pharmaceutical & biotechnology companies, CROs & CDMOs and others. Pharmaceutical & biotechnology companies dominated the segment in 2024. With the continuous expansion of R&D pipelines, increased investments in innovative therapies, and the globalization of clinical trials, pharmaceutical and biotechnology companies remain the largest consumers of clinical trial supplies, reinforcing their dominance in the market. Additionally, CROs and CDMOs are expanding their capabilities by integrating digital technologies such as AI-driven supply chain optimization, blockchain for traceability, and real-time inventory management to enhance efficiency and compliance. “North America: the largest share of the Clinical Trial Supplies market” The market is segmented by region into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. North America dominated the Clinical Trial Supplies market in 2024 and is estimated to continue dominance during the forecast period. US leads the North American market, driven by the presence of leading academic & research institutions, and significant investment in biotechnology. The growing adoption of decentralized trials, advanced cold chain logistics, and direct-to-patient (DTP) delivery models has further strengthened the U.S. market. Moreover, the presence of a well-established clinical trial infrastructure, advanced healthcare system, and strong government funding for drug development has contributed to the country's leading position. The increasing demand for biologics, biosimilars, and advanced therapies is driving the need for specialized supply chain services, cold chain logistics, and regulatory-compliant distribution networks. With continuous improvements in healthcare infrastructure, favorable government policies, and growing outsourcing trends, APAC is expected to experience robust growth in the clinical trial supplies market in the coming years. In-depth interviews have been conducted with chief executive officers (CEOs), Directors, and other executives from various key organizations operating in the Clinical Trial Supplies market. The primary interviews conducted for this report can be categorized as follows: • By Respondent: Supply Side- 70% and Demand Side 30% • By Designation: Managers - 45%, CXO & Directors - 30%, and Executives - 25% • By Region: North America -40%, Europe -25%, Asia-Pacific -25%, Latin America -5% and Middle East & Africa- 5% The prominent players operating in the Clinical Trial Supplies market are Almac Group (UK), Novo Holdings A/S (Denmark), Marken (UPS) (US), PCI Pharma Services (US), Sharp Services LLC (US), Thermo Fisher Scientific Inc. (US), Cencora, Inc. (US), Myonex (US), Clinigen Limited (UK), Inceptua Group (Luxembourg), Eurofins Scientific (Luxembourg), Paraxel International Corporation (US), ICON Plc (Ireland), IQVIA (US), Nuvissan GmbH (Germany), Aenova Holding GmbH (Germany), Klifo (Denmark), IPS Pharma (UK), Corex Logistic Limited (Ireland), Biocair (US), Piramal Group (India), Lonza (Switzerland), OCT Group LLC (Germany), Ancillare LP (US), N-SIDE (Belgium), Adallen Pharma (UK), Uniphar Group (Ireland), Clinical Services International (UK) and among others. Research Coverage: Clinical Trial Supplies market report is segmented based on services (Logistics & Distribution, Storage & Retention, Packaging, Labeling and Blinding{Primary Packaging, Secondary Packaging and Labeling & Binding}, Manufacturing, Comparator Sourcing , and Other Services), Phase ( Phase I, Phase II, Phase III, Phase IV and Phase BA/BE), Type (Small Molecules, Biologics [Monoclonal Antibodies, Vaccines and Others], Medical Devices), Therapeutic Area (Oncology, Neurology, Respiratory Disorder, Metabolic Disorder/Endocrinology, Cardiovascular System Disorders, Dermatology, Gastrointestinal, Immunological Disorder, Infectious Diseases, Psychiatry, Ophthalmology, Haematology, Genitourinary and Women's Health, and Others), End Users (pharmaceutical & biotechnology companies, CROs & CDMOs and others). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the Clinical Trial Supplies market. A detailed analysis of the key industry players has been done to provide insights into their business overview, services, key strategies, collaborations, partnerships, and agreements. New launches, collaborations and acquisitions, and recent developments associated with the Clinical Trial Supplies market. Key Benefits of Buying the Report: The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the Clinical Trial Supplies and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges. The report provides insights on the following pointers: • Analysis of key drivers ( Increasing Number of Clinical Trials, Technological Advancements in Supply Chain Management), restraints (High Cost of clinical trial supplies), opportunities (Rise of Decentralized & Direct-to-Patient (DTP) Trials) and Challenges ( managing global supply chains) influencing the growth of the market. • Service Development/Innovation: Detailed insights on upcoming technologies in Clinical Trial Supplies, research and development activities, and new service launches in the Clinical Trial Supplies market. • Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions. • Market Diversification: Exhaustive information about new services, untapped geographies, recent developments, and investments in the Clinical Trial Supplies market • Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players lmac Group (UK), Novo Holdings A/S (Denmark), Marken (UPS) (US), PCI Pharma Services (US), Sharp Services LLC (US), Thermo Fisher Scientific Inc. (US), Cencora, Inc. (US), Myonex (US), Clinigen Limited (UK), Inceptua Group (Luxembourg), Eurofins Scientific (Luxembourg), Paraxel International Corporation (US), ICON Plc (Ireland), IQVIA (US), Nuvissan GmbH (Germany) and among others
目錄 Table of Contents
1 INTRODUCTION 38 1.1 STUDY OBJECTIVES 38 1.2 MARKET DEFINITION 38 1.3 MARKET SCOPE 39 1.3.1 MARKETS & REGIONS COVERED 39 1.3.2 INCLUSIONS & EXCLUSIONS 40 1.3.3 YEARS CONSIDERED 40 1.3.4 CURRENCY CONSIDERED 41 1.4 STAKEHOLDERS 41 1.5 SUMMARY OF CHANGES 41 2 RESEARCH METHODOLOGY 43 2.1 RESEARCH DATA 43 2.1.1 SECONDARY DATA 44 2.1.2 PRIMARY RESEARCH 45 2.2 MARKET SIZE ESTIMATION 46 2.2.1 GLOBAL MARKET ESTIMATION 46 2.2.1.1 Insights from primary experts 48 2.2.2 SEGMENTAL MARKET ESTIMATION (TOP-DOWN APPROACH) 49 2.3 MARKET GROWTH RATE PROJECTIONS 50 2.4 DATA TRIANGULATION 52 2.5 RESEARCH ASSUMPTIONS 53 2.6 RESEARCH LIMITATIONS 54 2.7 RISK ANALYSIS 54 3 EXECUTIVE SUMMARY 55 4 PREMIUM INSIGHTS 60 4.1 CLINICAL TRIAL SUPPLIES MARKET OVERVIEW 60 4.2 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE AND COUNTRY (2024) 61 4.3 CLINICAL TRIAL SUPPLIES MARKET SHARE, BY TYPE, 2025 VS. 2030 61 4.4 CLINICAL TRIAL SUPPLIES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 62 5 MARKET OVERVIEW 63 5.1 INTRODUCTION 63 5.2 MARKET DYNAMICS 64 5.2.1 DRIVERS 65 5.2.1.1 Growth in clinical trials & drug development 65 5.2.1.2 Expansion of global and multicenter trials accelerating demand for clinical trial supplies 66 5.2.1.3 Rising demand for personalized medicine and biologics 66 5.2.2 RESTRAINTS 67 5.2.2.1 High costs associated with clinical trial supplies 67 5.2.3 OPPORTUNITIES 67 5.2.3.1 Rise in decentralized and virtual trials 67 5.2.3.2 Integration of digital technologies in supply chain management 68 5.2.4 CHALLENGES 68 5.2.4.1 Supply chain disruptions and drug shortages 68 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 69 5.4 VALUE CHAIN ANALYSIS 69 5.5 ECOSYSTEM ANALYSIS 72 5.5.1 CLINICAL TRIAL SUPPLIES MARKET: RAW MATERIAL PROVIDERS 73 5.5.2 CLINICAL TRIAL SUPPLIES MARKET: SERVICE PROVIDERS 73 5.5.3 CLINICAL TRIAL SUPPLIES MARKET: END USERS 74 5.5.4 CLINICAL TRIAL SUPPLIES MARKET: REGULATORY BODIES 74 5.6 PRICING ANALYSIS 75 5.6.1 AVERAGE SELLING PRICE, BY KEY PLAYER (QUALITATIVE) 75 5.6.2 INDICATIVE PRICE, BY SERVICE (QUALITATIVE) 76 5.7 INVESTMENT AND FUNDING SCENARIO 77 5.8 TECHNOLOGY ANALYSIS 77 5.8.1 KEY TECHNOLOGIES 77 5.8.1.1 Serialization & track-and-trace technologies 77 5.8.1.2 Interactive response technology (IRT/IVR/IWR) 78 5.8.1.3 Cold chain & temperature monitoring solutions 78 5.8.2 COMPLEMENTARY TECHNOLOGIES 78 5.8.2.1 Artificial intelligence (AI) & machine learning (ML) 78 5.8.2.2 Blockchain for supply chain transparency 78 5.8.3 ADJACENT TECHNOLOGIES 78 5.8.3.1 Cryopreservation & advanced storage technologies 78 5.8.3.2 Advanced robotics in warehousing & distribution 79 5.9 KEY CONFERENCES AND EVENTS, 2025–2026 79 5.10 REGULATORY LANDSCAPE 80 5.10.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 80 5.10.2 REGULATORY FRAMEWORK 83 5.10.2.1 North America 83 5.10.2.1.1 US 83 5.10.2.1.2 Canada 84 5.10.2.2 Europe 84 5.10.2.2.1 Germany 84 5.10.2.2.2 France 84 5.10.2.2.3 Italy 84 5.10.2.3 Asia Pacific 84 5.10.2.3.1 Japan 84 5.10.2.3.2 China 84 5.10.2.3.3 India 84 5.10.2.4 Latin America 85 5.10.2.4.1 Brazil 85 5.10.2.5 Middle East & Africa 85 5.10.2.5.1 GCC Countries 85 5.10.2.5.2 South Africa 85 5.11 PORTER’S FIVE FORCES ANALYSIS 85 5.11.1 THREAT OF NEW ENTRANTS 86 5.11.2 BARGAINING POWER OF SUPPLIERS 86 5.11.3 BARGAINING POWER OF BUYERS 87 5.11.4 THREAT OF SUBSTITUTES 87 5.11.5 INTENSITY OF COMPETITIVE RIVALRY 87 5.12 KEY STAKEHOLDERS AND BUYING CRITERIA 87 5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS 88 5.12.2 BUYING CRITERIA 89 5.13 IMPACT OF AI/GENERATIVE AI ON CLINICAL TRIAL SUPPLIES MARKET 90 5.13.1 INTRODUCTION 90 5.13.2 FUTURE OF GENERATIVE AI IN CLINICAL TRIAL SUPPLIES ECOSYSTEM 92 6 CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE 93 6.1 INTRODUCTION 94 6.2 LOGISTICS & DISTRIBUTION SERVICES 94 6.2.1 RISING DEMAND DUE TO INCREASING EMPHASIS ON CLINICAL DIAGNOSTICS TO SUPPORT MARKET GROWTH 94 6.3 COMPARATOR SOURCING SERVICES 98 6.3.1 RISING DEMAND FOR COMPARATOR SOURCING TO DRIVE MARKET 98 6.4 PACKAGING, LABELING, AND BLINDING SERVICES 101 6.4.1 PRIMARY PACKAGING SERVICES 105 6.4.1.1 Increasing demand for innovative drug formulations to support market growth 105 6.4.2 SECONDARY PACKAGING SERVICES 108 6.4.2.1 Increasing complexity of global clinical trials to propel market 108 6.4.3 LABELING & BLINDING SERVICES 111 6.4.3.1 Rising number of randomized and double-blind studies to propel market 111   6.5 MANUFACTURING SERVICES 114 6.5.1 RISING DEMAND FOR ULTRA-LOW-TEMPERATURE STORAGE TO DRIVE GROWTH 114 6.6 STORAGE & RETENTION SERVICES 117 6.6.1 RISING DEMAND FOR ULTRA-LOW-TEMPERATURE STORAGE TO DRIVE GROWTH 117 6.7 OTHER SERVICES 121 7 CLINICAL TRIAL SUPPLIES MARKET, BY PHASE 125 7.1 INTRODUCTION 126 7.2 PHASE III 126 7.2.1 DEVELOPMENT OF BIOLOGICS AND ADVANCED THERAPIES TO SUPPORT MARKET GROWTH 126 7.3 PHASE II 130 7.3.1 NEED FOR GREATER EFFICIENCY AND COMPLIANCE IN TRIAL LOGISTICS TO SUPPORT MARKET GROWTH 130 7.4 PHASE I 133 7.4.1 RISING COMPLEXITY OF INVESTIGATIONAL DRUGS TO DRIVE MARKET GROWTH 133 7.5 PHASE IV 137 7.5.1 INCREASING FOCUS ON PATIENT-CENTRIC APPROACHES TO DRIVE MARKET GROWTH 137 7.6 PHASE BA/BE 140 7.6.1 ACCELERATING GENERIC DRUG APPROVALS THROUGH OPTIMIZED BA/BE STUDIES TO SUPPORT MARKET GROWTH 140 8 CLINICAL TRIAL SUPPLIES MARKET, BY TYPE 144 8.1 INTRODUCTION 145 8.2 SMALL MOLECULES 145 8.2.1 HIGH VOLUME OF SMALL-MOLECULE CLINICAL TRIALS 145 8.3 BIOLOGICS 149 8.3.1 MONOCLONAL ANTIBODIES 153 8.3.1.1 Rising demand for monoclonal antibodies to drive growth 153 8.3.2 VACCINES 156 8.3.2.1 Increased focus on development of novel vaccines to drive growth 156 8.3.3 OTHER BIOLOGICS 160 8.4 MEDICAL DEVICES 163 8.4.1 RISING DEMAND FOR SPECIALIZED LOGISTICS IN MEDICAL DEVICE CLINICAL TRIALS TO DRIVE MARKET GROWTH 163 9 CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA 167 9.1 INTRODUCTION 168 9.2 ONCOLOGY 169 9.2.1 RISING DISEASE BURDEN TO SUPPORT MARKET GROWTH 169   9.3 NEUROLOGY 173 9.3.1 INCREASING R&D INVESTMENT TO SUPPORT MARKET GROWTH 173 9.4 RESPIRATORY DISORDERS 177 9.4.1 RISING INCIDENCE OF RESPIRATORY DISORDERS TO SUPPORT MARKET GROWTH 177 9.5 METABOLIC DISORDERS/ENDOCRINOLOGY 180 9.5.1 INCREASING GLOBAL DIABETES POPULATION TO SUPPORT MARKET GROWTH 180 9.6 CARDIOVASCULAR SYSTEM DISORDERS 184 9.6.1 RISING DEMAND IN CLINICAL DIAGNOSTICS TO PROPEL MARKET GROWTH 184 9.7 DERMATOLOGY 187 9.7.1 GROWING FOCUS ON DRUG DEVELOPMENT TO SUPPORT MARKET GROWTH 187 9.8 GASTROINTESTINAL SYSTEM DISORDERS 191 9.8.1 INCREASING INCIDENCE OF LIFESTYLE AND DIETARY RISK FACTORS TO DRIVE DEMAND 191 9.9 IMMUNOLOGICAL DISORDERS 194 9.9.1 GROWING CLINICAL RESEARCH TO SUPPORT MARKET GROWTH 194 9.10 INFECTIOUS DISEASES 198 9.10.1 RISING OUTBREAKS OF INFECTIOUS DISEASES TO SUPPORT MARKET GROWTH 198 9.11 PSYCHIATRY 202 9.11.1 RISING INCIDENCE OF PSYCHIATRIC DISORDERS TO PROPEL MARKET GROWTH 202 9.12 OPHTHALMOLOGY 205 9.12.1 RISING NUMBER OF OPHTHALMIC PIPELINE DRUGS TO AID MARKET GROWTH 205 9.13 HEMATOLOGY 209 9.13.1 INTEGRATION OF ADVANCED SUPPLY CHAIN TECHNOLOGIES TO FUEL MARKET GROWTH 209 9.14 GENITOURINARY & WOMEN’S HEALTH 212 9.14.1 RISING PREVALENCE OF CHRONIC DISORDERS IN WOMEN TO PROPEL MARKET GROWTH 212 9.15 OTHER THERAPEUTIC AREAS 216 10 CLINICAL TRIAL SUPPLIES MARKET, BY REGION 220 10.1 INTRODUCTION 221 10.2 NORTH AMERICA 221 10.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 222 10.2.2 US 227 10.2.2.1 Robust hospital infrastructure and drug research & development to stimulate growth 227 10.2.3 CANADA 230 10.2.3.1 Growing preference of pharmaceutical companies to conduct trials to favor growth 230   10.3 EUROPE 234 10.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 234 10.3.2 GERMANY 239 10.3.2.1 Growing focus on reducing approval timelines and high spending by global pharmaceutical players to propel market 239 10.3.3 UK 243 10.3.3.1 Expanding tax credits leading to encourage growth 243 10.3.4 FRANCE 246 10.3.4.1 Evolving regulatory landscape to stimulate growth 246 10.3.5 ITALY 250 10.3.5.1 Increasing number of drug approvals to accelerate growth 250 10.3.6 SPAIN 253 10.3.6.1 Favorable clinical trial network in public health system to sustain growth 253 10.3.7 SWITZERLAND 256 10.3.7.1 Presence of multinational corporations and small and medium-sized pharmaceutical companies to fuel market 256 10.3.8 NETHERLANDS 260 10.3.8.1 Increasing collaborations among pharmaceutical giants to promote growth 260 10.3.9 REST OF EUROPE 263 10.4 ASIA PACIFIC 267 10.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 267 10.4.2 CHINA 273 10.4.2.1 High proportion of domestic industry-sponsored trials to speed up growth 273 10.4.3 JAPAN 277 10.4.3.1 Increasing focus on lowering regulatory timelines to facilitate growth 277 10.4.4 INDIA 280 10.4.4.1 Rise in early-phase clinical trials to spur growth 280 10.4.5 AUSTRALIA 284 10.4.5.1 Increasing research funding to favor growth 284 10.4.6 SOUTH KOREA 287 10.4.6.1 Growing focus on new drug development research to drive market 287 10.4.7 SINGAPORE 291 10.4.7.1 Advanced research facilities to intensify growth 291 10.4.8 REST OF ASIA PACIFIC 294 10.5 LATIN AMERICA 298 10.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 298 10.5.2 BRAZIL 302 10.5.2.1 Regulatory improvements to support growth 302 10.5.3 MEXICO 306 10.5.3.1 Expanding landscape of clinical trials to boost market 306 10.5.4 REST OF LATIN AMERICA 309 10.6 MIDDLE EAST 312 10.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST 312 10.6.2 GCC COUNTRIES 317 10.6.2.1 Saudi Arabia 320 10.6.2.1.1 Booming investments in research infrastructure and life sciences development to aid growth 320 10.6.2.2 UAE 324 10.6.2.2.1 Increasing public-private partnerships and genomic research initiatives to augment growth 324 10.6.2.3 Rest of GCC Countries 327 10.6.3 REST OF MIDDLE EAST 330 10.7 AFRICA 333 10.7.1 GROWING DEMAND FOR OUTSOURCING SERVICES TO DRIVE MARKET GROWTH 333 10.7.2 MACROECONOMIC OUTLOOK FOR AFRICA 334 11 COMPETITIVE LANDSCAPE 338 11.1 INTRODUCTION 338 11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 338 11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN CLINICAL TRIAL SUPPLIES MARKET 338 11.3 REVENUE ANALYSIS, 2020–2024 340 11.4 MARKET SHARE ANALYSIS, 2024 341 11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 343 11.5.1 STARS 343 11.5.2 EMERGING LEADERS 343 11.5.3 PERVASIVE PLAYERS 343 11.5.4 PARTICIPANTS 343 11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 345 11.5.5.1 Company footprint 345 11.5.5.2 Region footprint 346 11.5.5.3 Service footprint 347 11.5.5.4 Type footprint 348 11.5.5.5 End-user footprint 349 11.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 349 11.6.1 PROGRESSIVE COMPANIES 349 11.6.2 RESPONSIVE COMPANIES 349 11.6.3 DYNAMIC COMPANIES 350 11.6.4 STARTING BLOCKS 350 11.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024 351 11.6.5.1 Detailed list of key startups/SMEs 351 11.6.5.2 Competitive benchmarking of key startups/SMEs 352   11.7 COMPANY VALUATION & FINANCIAL METRICS 353 11.7.1 COMPANY VALUATION 353 11.7.2 FINANCIAL METRICS 353 11.8 BRAND/SERVICE COMPARISON 354 11.9 COMPETITIVE SCENARIO 355 11.9.1 DEALS 355 11.9.2 EXPANSIONS 356 12 COMPANY PROFILES 357 12.1 KEY PLAYERS 357 12.1.1 THERMO FISHER SCIENTIFIC INC. 357 12.1.1.1 Business overview 357 12.1.1.2 Services offered 358 12.1.1.3 Recent developments 359 12.1.1.3.1 Service launches 359 12.1.1.3.2 Deals 359 12.1.1.3.3 Expansions 360 12.1.1.4 MnM view 360 12.1.1.4.1 Right to win 360 12.1.1.4.2 Strategic choices 360 12.1.1.4.3 Weaknesses & competitive threats 360 12.1.2 NOVO HOLDINGS A/S 361 12.1.2.1 Business overview 361 12.1.2.2 Services offered 362 12.1.2.3 Recent developments 363 12.1.2.3.1 Deals 363 12.1.2.3.2 Expansions 364 12.1.2.4 MnM view 364 12.1.2.4.1 Right to win 364 12.1.2.4.2 Strategic choices 364 12.1.2.4.3 Weaknesses & competitive threats 365 12.1.3 UNITED PARCEL SERVICE OF AMERICA, INC. 366 12.1.3.1 Business overview 366 12.1.3.2 Services offered 366 12.1.3.3 MnM view 367 12.1.3.3.1 Right to win 367 12.1.3.3.2 Strategic choices 367 12.1.3.3.3 Weaknesses & competitive threats 368   12.1.4 EUROFINS SCIENTIFIC 369 12.1.4.1 Business overview 369 12.1.4.2 Services offered 370 12.1.4.3 MnM view 371 12.1.4.3.1 Right to win 371 12.1.4.3.2 Strategic choices 371 12.1.4.3.3 Weaknesses & competitive threats 371 12.1.5 PIRAMAL PHARMA LIMITED 372 12.1.5.1 Business overview 372 12.1.5.2 Services offered 373 12.1.5.3 MnM view 374 12.1.5.3.1 Right to win 374 12.1.5.3.2 Strategic choices 374 12.1.5.3.3 Weaknesses & competitive threats 374 12.1.6 IQVIA 375 12.1.6.1 Business overview 375 12.1.6.2 Services offered 377 12.1.7 ICON PLC 378 12.1.7.1 Business overview 378 12.1.7.2 Services offered 379 12.1.7.3 Recent developments 380 12.1.7.3.1 Deals 380 12.1.8 LONZA 381 12.1.8.1 Business overview 381 12.1.8.2 Services offered 382 12.1.8.3 Recent developments 382 12.1.8.3.1 Deals 382 12.1.9 UNIPHAR GROUP PLC 383 12.1.9.1 Business overview 383 12.1.9.2 Services offered 384 12.1.10 ALMAC GROUP 385 12.1.10.1 Business overview 385 12.1.10.2 Services offered 385 12.1.10.3 Recent developments 386 12.1.10.3.1 Expansions 386 12.1.11 SHARP SERVICES, LLC 387 12.1.11.1 Business overview 387 12.1.11.2 Services offered 387 12.1.12 PCI PHARMA SERVICES 389 12.1.12.1 Business overview 389 12.1.12.2 Services offered 389 12.1.12.3 Recent developments 390 12.1.12.3.1 Expansions 390 12.1.13 PAREXEL INTERNATIONAL (MA) CORPORATION 391 12.1.13.1 Business overview 391 12.1.13.2 Services offered 391 12.1.13.3 Recent developments 392 12.1.13.3.1 Deals 392 12.1.14 BIOCAIR 393 12.1.14.1 Business overview 393 12.1.14.2 Services offered 393 12.2 OTHER PLAYERS 394 12.2.1 CENCORA, INC. 394 12.2.2 CLINIGEN LIMITED 395 12.2.3 KLIFO 396 12.2.4 IPS PHARMA 397 12.2.5 COREX LOGISTICS LIMITED 398 12.2.6 OCT GROUP LLC 399 12.2.7 MYONEX 400 12.2.8 INCEPTUA GROUP 401 12.2.9 ANCILLARE, LP 402 12.2.10 ADALLEN PHARMA 403 12.2.11 CLINICAL SERVICES INTERNATIONAL (CSI) 404 12.2.12 NUVISAN GMBH 405 12.2.13 AENOVA HOLDING GMBH 406 13 APPENDIX 407 13.1 DISCUSSION GUIDE 407 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 411 13.3 CUSTOMIZATION OPTIONS 413 13.4 RELATED REPORTS 413 13.5 AUTHOR DETAILS 414
圖表清單 List of Tables & Figures
TABLE 1 IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS 51 TABLE 2 CLINICAL TRIAL SUPPLIES MARKET: RISK ASSESSMENT ANALYSIS 54 TABLE 3 CLINICAL TRIAL SUPPLIES MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS 64 TABLE 4 CLINICAL TRIAL SUPPLIES MARKET: PRODUCT MANUFACTURERS 73 TABLE 5 CLINICAL TRIAL SUPPLIES MARKET: SERVICE PROVIDERS 73 TABLE 6 CLINICAL TRIAL SUPPLIES MARKET: END USERS 74 TABLE 7 CLINICAL TRIAL SUPPLIES MARKET: REGULATORY BODIES 74 TABLE 8 CLINICAL TRIAL SUPPLIES MARKET: KEY CONFERENCES AND EVENTS, 2025–2026 79 TABLE 9 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 80 TABLE 10 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 81 TABLE 11 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 82 TABLE 12 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 83 TABLE 13 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 83 TABLE 14 CLINICAL TRIAL SUPPLIES MARKET: PORTER’S FIVE FORCES ANALYSIS 85 TABLE 15 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER 88 TABLE 16 KEY BUYING CRITERIA FOR CLINICAL TRIAL SUPPLIES PRODUCTS, BY END USER 89 TABLE 17 CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2023–2030 (USD MILLION) 94 TABLE 18 CLINICAL TRIAL SUPPLIES MARKET FOR LOGISTICS & DISTRIBUTION SERVICES, BY REGION, 2023–2030 (USD MILLION) 95 TABLE 19 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR LOGISTICS & DISTRIBUTION SERVICES, BY COUNTRY, 2023–2030 (USD MILLION) 95 TABLE 20 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR LOGISTICS & DISTRIBUTION SERVICES, BY COUNTRY, 2023–2030 (USD MILLION) 96 TABLE 21 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR LOGISTICS & DISTRIBUTION SERVICES, BY COUNTRY, 2023–2030 (USD MILLION) 96 TABLE 22 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR LOGISTICS & DISTRIBUTION SERVICES, BY COUNTRY, 2023–2030 (USD MILLION) 97 TABLE 23 MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET FOR LOGISTICS & DISTRIBUTION SERVICES, BY REGION, 2023–2030 (USD MILLION) 97 TABLE 24 GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET FOR LOGISTICS & DISTRIBUTION SERVICES, BY COUNTRY, 2023–2030 (USD MILLION) 97 TABLE 25 CLINICAL TRIAL SUPPLIES MARKET FOR COMPARATOR SOURCING SERVICES, BY REGION, 2023–2030 (USD MILLION) 98 TABLE 26 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR COMPARATOR SOURCING SERVICES, BY COUNTRY, 2023–2030 (USD MILLION) 99 TABLE 27 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR COMPARATOR SOURCING SERVICES, BY COUNTRY, 2023–2030 (USD MILLION) 99 TABLE 28 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR COMPARATOR SOURCING SERVICES, BY COUNTRY, 2023–2030 (USD MILLION) 100 TABLE 29 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR COMPARATOR SOURCING SERVICES, BY COUNTRY, 2023–2030 (USD MILLION) 100 TABLE 30 MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET FOR COMPARATOR SOURCING SERVICES, BY REGION, 2023–2030 (USD MILLION) 100 TABLE 31 GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET FOR COMPARATOR SOURCING SERVICES, BY COUNTRY, 2023–2030 (USD MILLION) 101 TABLE 32 CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY TYPE, 2023–2030 (USD MILLION) 102 TABLE 33 CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY REGION, 2023–2030 (USD MILLION) 102 TABLE 34 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY COUNTRY, 2023–2030 (USD MILLION) 102 TABLE 35 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY COUNTRY, 2023–2030 (USD MILLION) 103 TABLE 36 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY COUNTRY, 2023–2030 (USD MILLION) 103 TABLE 37 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY COUNTRY, 2023–2030 (USD MILLION) 104 TABLE 38 MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY REGION, 2023–2030 (USD MILLION) 104 TABLE 39 GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY COUNTRY, 2023–2030 (USD MILLION) 104 TABLE 40 PRIMARY PACKAGING SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 105 TABLE 41 NORTH AMERICA: PRIMARY PACKAGING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 105 TABLE 42 EUROPE: PRIMARY PACKAGING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 106 TABLE 43 ASIA PACIFIC: PRIMARY PACKAGING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 106 TABLE 44 LATIN AMERICA: PRIMARY PACKAGING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 107 TABLE 45 MIDDLE EAST: PRIMARY PACKAGING SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 107 TABLE 46 GCC COUNTRIES: PRIMARY PACKAGING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 107 TABLE 47 SECONDARY PACKAGING SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 108 TABLE 48 NORTH AMERICA: SECONDARY PACKAGING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 108 TABLE 49 EUROPE: SECONDARY PACKAGING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 109 TABLE 50 ASIA PACIFIC: SECONDARY PACKAGING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 109 TABLE 51 LATIN AMERICA: SECONDARY PACKAGING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 110 TABLE 52 MIDDLE EAST: SECONDARY PACKAGING SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 110 TABLE 53 GCC COUNTRIES: SECONDARY PACKAGING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 110 TABLE 54 LABELING & BLINDING SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 111 TABLE 55 NORTH AMERICA: LABELING & BLINDING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 111 TABLE 56 EUROPE: LABELING & BLINDING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 112 TABLE 57 ASIA PACIFIC: LABELING & BLINDING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 112 TABLE 58 LATIN AMERICA: LABELING & BLINDING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 113 TABLE 59 MIDDLE EAST: LABELING & BLINDING SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 113 TABLE 60 GCC COUNTRIES: LABELING & BLINDING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 113 TABLE 61 CLINICAL TRIAL SUPPLIES MARKET FOR MANUFACTURING SERVICES, BY REGION, 2023–2030 (USD MILLION) 114 TABLE 62 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR MANUFACTURING SERVICES, BY COUNTRY, 2023–2030 (USD MILLION) 115 TABLE 63 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR MANUFACTURING SERVICES, BY COUNTRY, 2023–2030 (USD MILLION) 115 TABLE 64 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR MANUFACTURING SERVICES, BY COUNTRY, 2023–2030 (USD MILLION) 116 TABLE 65 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR MANUFACTURING SERVICES, BY COUNTRY, 2023–2030 (USD MILLION) 116 TABLE 66 MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET FOR MANUFACTURING SERVICES, BY REGION, 2023–2030 (USD MILLION) 116 TABLE 67 GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET FOR MANUFACTURING SERVICES, BY COUNTRY, 2023–2030 (USD MILLION) 117 TABLE 68 CLINICAL TRIAL SUPPLIES MARKET FOR STORAGE & RETENTION SERVICES, BY REGION, 2023–2030 (USD MILLION) 118 TABLE 69 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR STORAGE & RETENTION SERVICES, BY COUNTRY, 2023–2030 (USD MILLION) 118 TABLE 70 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR STORAGE & RETENTION SERVICES, BY COUNTRY, 2023–2030 (USD MILLION) 119 TABLE 71 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR STORAGE & RETENTION SERVICES, BY COUNTRY, 2023–2030 (USD MILLION) 119 TABLE 72 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR STORAGE & RETENTION SERVICES, BY COUNTRY, 2023–2030 (USD MILLION) 120 TABLE 73 MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET FOR STORAGE & RETENTION SERVICES, BY REGION, 2023–2030 (USD MILLION) 120 TABLE 74 GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET FOR STORAGE & RETENTION SERVICES, BY COUNTRY, 2023–2030 (USD MILLION) 120 TABLE 75 CLINICAL TRIAL SUPPLIES MARKET FOR OTHER SERVICES, BY REGION, 2023–2030 (USD MILLION) 121 TABLE 76 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR OTHER SERVICES, BY COUNTRY, 2023–2030 (USD MILLION) 122 TABLE 77 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR OTHER SERVICES, BY COUNTRY, 2023–2030 (USD MILLION) 122 TABLE 78 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR OTHER SERVICES, BY COUNTRY, 2023–2030 (USD MILLION) 123 TABLE 79 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR OTHER SERVICES, BY COUNTRY, 2023–2030 (USD MILLION) 123 TABLE 80 MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET FOR OTHER SERVICES, BY REGION, 2023–2030 (USD MILLION) 123 TABLE 81 GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET FOR OTHER SERVICES, BY COUNTRY, 2023–2030 (USD MILLION) 124 TABLE 82 CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2023–2030 (USD MILLION) 126 TABLE 83 CLINICAL TRIAL SUPPLIES MARKET FOR PHASE III TRIALS, BY REGION, 2023–2030 (USD MILLION) 127 TABLE 84 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE III TRIALS, BY COUNTRY, 2023–2030 (USD MILLION) 127 TABLE 85 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE III TRIALS, BY COUNTRY, 2023–2030 (USD MILLION) 128 TABLE 86 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE III TRIALS, BY COUNTRY, 2023–2030 (USD MILLION) 128 TABLE 87 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE III TRIALS, BY COUNTRY, 2023–2030 (USD MILLION) 129 TABLE 88 MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE III TRIALS, BY REGION, 2023–2030 (USD MILLION) 129 TABLE 89 GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE III TRIALS, BY COUNTRY, 2023–2030 (USD MILLION) 129 TABLE 90 CLINICAL TRIAL SUPPLIES MARKET FOR PHASE II TRIALS, BY REGION, 2023–2030 (USD MILLION) 130 TABLE 91 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE II TRIALS, BY COUNTRY, 2023–2030 (USD MILLION) 131 TABLE 92 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE II TRIALS, BY COUNTRY, 2023–2030 (USD MILLION) 131 TABLE 93 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE II TRIALS, BY COUNTRY, 2023–2030 (USD MILLION) 132 TABLE 94 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE II TRIALS, BY COUNTRY, 2023–2030 (USD MILLION) 132 TABLE 95 MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE II TRIALS, BY REGION, 2023–2030 (USD MILLION) 132 TABLE 96 GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE II TRIALS, BY COUNTRY, 2023–2030 (USD MILLION) 133 TABLE 97 CLINICAL TRIAL SUPPLIES MARKET FOR PHASE I TRIALS, BY REGION, 2023–2030 (USD MILLION) 134 TABLE 98 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE I TRIALS, BY COUNTRY, 2023–2030 (USD MILLION) 134 TABLE 99 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE I TRIALS, BY COUNTRY, 2023–2030 (USD MILLION) 135 TABLE 100 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE I TRIALS, BY COUNTRY, 2023–2030 (USD MILLION) 135 TABLE 101 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE I TRIALS, BY COUNTRY, 2023–2030 (USD MILLION) 136 TABLE 102 MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE I TRIALS, BY REGION, 2023–2030 (USD MILLION) 136 TABLE 103 GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE I TRIALS, BY COUNTRY, 2023–2030 (USD MILLION) 136 TABLE 104 CLINICAL TRIAL SUPPLIES MARKET FOR PHASE IV TRIALS, BY REGION, 2023–2030 (USD MILLION) 137 TABLE 105 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE IV TRIALS, BY COUNTRY, 2023–2030 (USD MILLION) 138 TABLE 106 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE IV TRIALS, BY COUNTRY, 2023–2030 (USD MILLION) 138 TABLE 107 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE IV TRIALS, BY COUNTRY, 2023–2030 (USD MILLION) 139 TABLE 108 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE IV TRIALS, BY COUNTRY, 2023–2030 (USD MILLION) 139 TABLE 109 MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE IV TRIALS, BY REGION, 2023–2030 (USD MILLION) 139 TABLE 110 GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE IV TRIALS, BY COUNTRY, 2023–2030 (USD MILLION) 140 TABLE 111 CLINICAL TRIAL SUPPLIES MARKET FOR PHASE BA/BE STUDIES, BY REGION, 2023–2030 (USD MILLION) 141 TABLE 112 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE BA/BE STUDIES, BY COUNTRY, 2023–2030 (USD MILLION) 141 TABLE 113 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE BA/BE STUDIES, BY COUNTRY, 2023–2030 (USD MILLION) 142 TABLE 114 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE BA/BE STUDIES, BY COUNTRY, 2023–2030 (USD MILLION) 142 TABLE 115 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE BA/BE STUDIES, BY COUNTRY, 2023–2030 (USD MILLION) 143 TABLE 116 MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE BA/BE STUDIES, BY REGION, 2023–2030 (USD MILLION) 143 TABLE 117 GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE BA/BE STUDIES, BY COUNTRY, 2023–2030 (USD MILLION) 143 TABLE 118 CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 145 TABLE 119 CLINICAL TRIAL SUPPLIES MARKET FOR SMALL MOLECULES, BY REGION, 2023–2030 (USD MILLION) 146 TABLE 120 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR SMALL MOLECULES, BY COUNTRY, 2023–2030 (USD MILLION) 146 TABLE 121 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR SMALL MOLECULES, BY COUNTRY, 2023–2030 (USD MILLION) 147 TABLE 122 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR SMALL MOLECULES, BY COUNTRY, 2023–2030 (USD MILLION) 147 TABLE 123 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR SMALL MOLECULES, BY COUNTRY, 2023–2030 (USD MILLION) 148 TABLE 124 MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET FOR SMALL MOLECULES, BY REGION, 2023–2030 (USD MILLION) 148 TABLE 125 GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET FOR SMALL MOLECULES, BY COUNTRY, 2023–2030 (USD MILLION) 148 TABLE 126 CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGICS, BY TYPE, 2023–2030 (USD MILLION) 149 TABLE 127 CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGICS, BY REGION, 2023–2030 (USD MILLION) 150 TABLE 128 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGICS, BY COUNTRY, 2023–2030 (USD MILLION) 150 TABLE 129 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGICS, BY COUNTRY, 2023–2030 (USD MILLION) 151 TABLE 130 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGICS, BY COUNTRY, 2023–2030 (USD MILLION) 151 TABLE 131 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGICS, BY COUNTRY, 2023–2030 (USD MILLION) 152 TABLE 132 MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGICS, BY REGION, 2023–2030 (USD MILLION) 152 TABLE 133 GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGICS, BY COUNTRY, 2023–2030 (USD MILLION) 152 TABLE 134 CLINICAL TRIAL SUPPLIES MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2023–2030 (USD MILLION) 153 TABLE 135 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2023–2030 (USD MILLION) 154 TABLE 136 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2023–2030 (USD MILLION) 154 TABLE 137 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2023–2030 (USD MILLION) 155 TABLE 138 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2023–2030 (USD MILLION) 155 TABLE 139 MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2023–2030 (USD MILLION) 155 TABLE 140 GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2023–2030 (USD MILLION) 156 TABLE 141 CLINICAL TRIAL SUPPLIES MARKET FOR VACCINES, BY REGION, 2023–2030 (USD MILLION) 157 TABLE 142 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR VACCINES, BY COUNTRY, 2023–2030 (USD MILLION) 157 TABLE 143 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR VACCINES, BY COUNTRY, 2023–2030 (USD MILLION) 158 TABLE 144 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR VACCINES, BY COUNTRY, 2023–2030 (USD MILLION) 158 TABLE 145 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR VACCINES, BY COUNTRY, 2023–2030 (USD MILLION) 159 TABLE 146 MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET FOR VACCINES, BY REGION, 2023–2030 (USD MILLION) 159 TABLE 147 GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET FOR VACCINES, BY COUNTRY, 2023–2030 (USD MILLION) 159 TABLE 148 CLINICAL TRIAL SUPPLIES MARKET FOR OTHER BIOLOGICS, BY REGION, 2023–2030 (USD MILLION) 160 TABLE 149 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR OTHER BIOLOGICS, BY COUNTRY, 2023–2030 (USD MILLION) 161 TABLE 150 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR OTHER BIOLOGICS, BY COUNTRY, 2023–2030 (USD MILLION) 161 TABLE 151 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR OTHER BIOLOGICS, BY COUNTRY, 2023–2030 (USD MILLION) 162 TABLE 152 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR OTHER BIOLOGICS, BY COUNTRY, 2023–2030 (USD MILLION) 162 TABLE 153 MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET FOR OTHER BIOLOGICS, BY REGION, 2023–2030 (USD MILLION) 162 TABLE 154 GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET FOR OTHER BIOLOGICS, BY COUNTRY, 2023–2030 (USD MILLION) 163 TABLE 155 CLINICAL TRIAL SUPPLIES MARKET FOR MEDICAL DEVICES, BY REGION, 2023–2030 (USD MILLION) 164 TABLE 156 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR MEDICAL DEVICES, BY COUNTRY, 2023–2030 (USD MILLION) 164 TABLE 157 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR MEDICAL DEVICES, BY COUNTRY, 2023–2030 (USD MILLION) 165 TABLE 158 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR MEDICAL DEVICES, BY COUNTRY, 2023–2030 (USD MILLION) 165 TABLE 159 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR MEDICAL DEVICES, BY COUNTRY, 2023–2030 (USD MILLION) 166 TABLE 160 MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET FOR MEDICAL DEVICES, BY REGION, 2023–2030 (USD MILLION) 166 TABLE 161 GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET FOR MEDICAL DEVICES, BY COUNTRY, 2023–2030 (USD MILLION) 166 TABLE 162 CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 168 TABLE 163 US: NUMBER OF NEW CANCER CASES, BY TYPE, 2022 VS. 2040 169 TABLE 164 CLINICAL TRIAL SUPPLIES MARKET FOR ONCOLOGY, BY REGION, 2023–2030 (USD MILLION) 170 TABLE 165 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 170 TABLE 166 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 171 TABLE 167 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 171 TABLE 168 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 172 TABLE 169 MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET FOR ONCOLOGY, BY REGION, 2023–2030 (USD MILLION) 172 TABLE 170 GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 172 TABLE 171 CLINICAL TRIAL SUPPLIES MARKET FOR NEUROLOGY, BY REGION, 2023–2030 (USD MILLION) 174 TABLE 172 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR NEUROLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 174 TABLE 173 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR NEUROLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 175 TABLE 174 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR NEUROLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 175 TABLE 175 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR NEUROLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 176 TABLE 176 MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET FOR NEUROLOGY, BY REGION, 2023–2030 (USD MILLION) 176 TABLE 177 GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET FOR NEUROLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 176 TABLE 178 CLINICAL TRIAL SUPPLIES MARKET FOR RESPIRATORY DISORDERS, BY REGION, 2023–2030 (USD MILLION) 177 TABLE 179 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 178 TABLE 180 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 178 TABLE 181 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 179 TABLE 182 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 179 TABLE 183 MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET FOR RESPIRATORY DISORDERS, BY REGION, 2023–2030 (USD MILLION) 179 TABLE 184 GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 180 TABLE 185 CLINICAL TRIAL SUPPLIES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY REGION, 2023–2030 (USD MILLION) 181 TABLE 186 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 181 TABLE 187 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 182 TABLE 188 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 182 TABLE 189 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 183 TABLE 190 MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY REGION, 2023–2030 (USD MILLION) 183 TABLE 191 GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 183 TABLE 192 CLINICAL TRIAL SUPPLIES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY REGION, 2023–2030 (USD MILLION) 184 TABLE 193 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 185 TABLE 194 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 185 TABLE 195 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 186 TABLE 196 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 186 TABLE 197 MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY REGION, 2023–2030 (USD MILLION) 186 TABLE 198 GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 187 TABLE 199 CLINICAL TRIAL SUPPLIES MARKET FOR DERMATOLOGY, BY REGION, 2023–2030 (USD MILLION) 188 TABLE 200 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR DERMATOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 188 TABLE 201 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR DERMATOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 189 TABLE 202 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR DERMATOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 189 TABLE 203 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR DERMATOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 190 TABLE 204 MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET FOR DERMATOLOGY, BY REGION, 2023–2030 (USD MILLION) 190 TABLE 205 GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET FOR DERMATOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 190 TABLE 206 CLINICAL TRIAL SUPPLIES MARKET FOR GASTROINTESTINAL SYSTEM DISORDERS, BY REGION, 2023–2030 (USD MILLION) 191 TABLE 207 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR GASTROINTESTINAL SYSTEM DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 192 TABLE 208 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR GASTROINTESTINAL SYSTEM DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 192 TABLE 209 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR GASTROINTESTINAL SYSTEM DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 193 TABLE 210 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR GASTROINTESTINAL SYSTEM DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 193 TABLE 211 MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET FOR GASTROINTESTINAL SYSTEM DISORDERS, BY REGION, 2023–2030 (USD MILLION) 194 TABLE 212 GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET FOR GASTROINTESTINAL SYSTEM DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 194 TABLE 213 CLINICAL TRIAL SUPPLIES MARKET FOR IMMUNOLOGICAL DISORDERS, BY REGION, 2023–2030 (USD MILLION) 195 TABLE 214 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 195 TABLE 215 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 196 TABLE 216 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 196 TABLE 217 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 197 TABLE 218 MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET FOR IMMUNOLOGICAL DISORDERS, BY REGION, 2023–2030 (USD MILLION) 197 TABLE 219 GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 197 TABLE 220 CLINICAL TRIAL SUPPLIES MARKET FOR INFECTIOUS DISEASES, BY REGION, 2023–2030 (USD MILLION) 199 TABLE 221 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 199 TABLE 222 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 200 TABLE 223 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 200 TABLE 224 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 201 TABLE 225 MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET FOR INFECTIOUS DISEASES, BY REGION, 2023–2030 (USD MILLION) 201 TABLE 226 GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 201 TABLE 227 CLINICAL TRIAL SUPPLIES MARKET FOR PSYCHIATRY, BY REGION, 2023–2030 (USD MILLION) 202 TABLE 228 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR PSYCHIATRY, BY COUNTRY, 2023–2030 (USD MILLION) 203 TABLE 229 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR PSYCHIATRY, BY COUNTRY, 2023–2030 (USD MILLION) 203 TABLE 230 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR PSYCHIATRY, BY COUNTRY, 2023–2030 (USD MILLION) 204 TABLE 231 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR PSYCHIATRY, BY COUNTRY, 2023–2030 (USD MILLION) 204 TABLE 232 MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET FOR PSYCHIATRY, BY REGION, 2023–2030 (USD MILLION) 204 TABLE 233 GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET FOR PSYCHIATRY, BY COUNTRY, 2023–2030 (USD MILLION) 205 TABLE 234 CLINICAL TRIAL SUPPLIES MARKET FOR OPHTHALMOLOGY, BY REGION, 2023–2030 (USD MILLION) 206 TABLE 235 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 206 TABLE 236 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 207 TABLE 237 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 207 TABLE 238 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 208 TABLE 239 MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET FOR OPHTHALMOLOGY, BY REGION, 2023–2030 (USD MILLION) 208 TABLE 240 GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 208 TABLE 241 CLINICAL TRIAL SUPPLIES MARKET FOR HEMATOLOGY, BY REGION, 2023–2030 (USD MILLION) 209 TABLE 242 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR HEMATOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 210 TABLE 243 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR HEMATOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 210 TABLE 244 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR HEMATOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 211 TABLE 245 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR HEMATOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 211 TABLE 246 MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET FOR HEMATOLOGY, BY REGION, 2023–2030 (USD MILLION) 211 TABLE 247 GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET FOR HEMATOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 212 TABLE 248 CLINICAL TRIAL SUPPLIES MARKET FOR GENITOURINARY & WOMEN’S HEALTH, BY REGION, 2023–2030 (USD MILLION) 213 TABLE 249 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR GENITOURINARY & WOMEN’S HEALTH, BY COUNTRY, 2023–2030 (USD MILLION) 213 TABLE 250 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR GENITOURINARY & WOMEN’S HEALTH, BY COUNTRY, 2023–2030 (USD MILLION) 214 TABLE 251 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR GENITOURINARY & WOMEN’S HEALTH, BY COUNTRY, 2023–2030 (USD MILLION) 214 TABLE 252 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR GENITOURINARY & WOMEN’S HEALTH, BY COUNTRY, 2023–2030 (USD MILLION) 215 TABLE 253 MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET FOR GENITOURINARY & WOMEN’S HEALTH, BY REGION, 2023–2030 (USD MILLION) 215 TABLE 254 GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET FOR GENITOURINARY & WOMEN’S HEALTH, BY COUNTRY, 2023–2030 (USD MILLION) 215 TABLE 255 CLINICAL TRIAL SUPPLIES MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2023–2030 (USD MILLION) 216 TABLE 256 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023–2030 (USD MILLION) 217 TABLE 257 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023–2030 (USD MILLION) 217 TABLE 258 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023–2030 (USD MILLION) 218 TABLE 259 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023–2030 (USD MILLION) 218 TABLE 260 MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2023–2030 (USD MILLION) 218 TABLE 261 GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023–2030 (USD MILLION) 219 TABLE 262 CLINICAL TRIAL SUPPLIES MARKET, BY REGION, 2023–2030 (USD MILLION) 221 TABLE 263 NORTH AMERICA: KEY MACROECONOMIC INDICATORS 222 TABLE 264 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 223 TABLE 265 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2023–2030 (USD MILLION) 224 TABLE 266 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY TYPE, 2023–2030 (USD MILLION) 224 TABLE 267 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2023–2030 (USD MILLION) 225 TABLE 268 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 225 TABLE 269 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGICS, BY TYPE, 2023–2030 (USD MILLION) 225 TABLE 270 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 226 TABLE 271 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2023–2030 (USD MILLION) 226 TABLE 272 US: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2023–2030 (USD MILLION) 227 TABLE 273 US: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY TYPE, 2023–2030 (USD MILLION) 228 TABLE 274 US: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2023–2030 (USD MILLION) 228 TABLE 275 US: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 228 TABLE 276 US: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGICS, BY TYPE, 2023–2030 (USD MILLION) 229 TABLE 277 US: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 229 TABLE 278 US: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2023–2030 (USD MILLION) 230 TABLE 279 CANADA: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2023–2030 (USD MILLION) 231 TABLE 280 CANADA: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY TYPE, 2023–2030 (USD MILLION) 231 TABLE 281 CANADA: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2023–2030 (USD MILLION) 232 TABLE 282 CANADA: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 232 TABLE 283 CANADA: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGICS, BY TYPE, 2023–2030 (USD MILLION) 232 TABLE 284 CANADA: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 233 TABLE 285 CANADA: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2023–2030 (USD MILLION) 233 TABLE 286 EUROPE: KEY MACROECONOMIC INDICATORS 235 TABLE 287 EUROPE: CLINICAL TRIAL SUPPLIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 235 TABLE 288 EUROPE: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2023–2030 (USD MILLION) 236 TABLE 289 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY TYPE, 2023–2030 (USD MILLION) 236 TABLE 290 EUROPE: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2023–2030 (USD MILLION) 237 TABLE 291 EUROPE: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 237 TABLE 292 EUROPE: CLINICAL TRIAL SUPPLIES MARKE FOR BIOLOGICS, BY TYPE, 2023–2030 (USD MILLION) 237 TABLE 293 EUROPE: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 238 TABLE 294 EUROPE: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2023–2030 (USD MILLION) 238 TABLE 295 GERMANY: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2023–2030 (USD MILLION) 240 TABLE 296 GERMANY: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY TYPE, 2023–2030 (USD MILLION) 240 TABLE 297 GERMANY: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2023–2030 (USD MILLION) 241 TABLE 298 GERMANY: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 241 TABLE 299 GERMANY: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGICS, BY TYPE, 2023–2030 (USD MILLION) 241 TABLE 300 GERMANY: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 242 TABLE 301 GERMANY: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2023–2030 (USD MILLION) 242 TABLE 302 UK: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2023–2030 (USD MILLION) 243 TABLE 303 UK: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY TYPE, 2023–2030 (USD MILLION) 244 TABLE 304 UK: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2023–2030 (USD MILLION) 244 TABLE 305 UK: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 244 TABLE 306 UK: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGICS, BY TYPE, 2023–2030 (USD MILLION) 245 TABLE 307 UK: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 245 TABLE 308 UK: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2023–2030 (USD MILLION) 246 TABLE 309 FRANCE: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2023–2030 (USD MILLION) 247 TABLE 310 FRANCE: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY TYPE, 2023–2030 (USD MILLION) 247 TABLE 311 FRANCE: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2023–2030 (USD MILLION) 248 TABLE 312 FRANCE: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 248 TABLE 313 FRANCE: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGICS, BY TYPE, 2023–2030 (USD MILLION) 248 TABLE 314 FRANCE: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 249 TABLE 315 FRANCE: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2023–2030 (USD MILLION) 249 TABLE 316 ITALY: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2023–2030 (USD MILLION) 250 TABLE 317 ITALY: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY TYPE, 2023–2030 (USD MILLION) 251 TABLE 318 ITALY: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2023–2030 (USD MILLION) 251 TABLE 319 ITALY: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 251 TABLE 320 ITALY: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGICS, BY TYPE, 2023–2030 (USD MILLION) 252 TABLE 321 ITALY: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 252 TABLE 322 ITALY: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2023–2030 (USD MILLION) 253 TABLE 323 SPAIN: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2023–2030 (USD MILLION) 253 TABLE 324 SPAIN: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY TYPE, 2023–2030 (USD MILLION) 254 TABLE 325 SPAIN: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2023–2030 (USD MILLION) 254 TABLE 326 SPAIN: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 254 TABLE 327 SPAIN: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGICS, BY TYPE, 2023–2030 (USD MILLION) 255 TABLE 328 SPAIN: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 255 TABLE 329 SPAIN: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2023–2030 (USD MILLION) 256 TABLE 330 SWITZERLAND: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2023–2030 (USD MILLION) 257 TABLE 331 SWITZERLAND: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY TYPE, 2023–2030 (USD MILLION) 257 TABLE 332 SWITZERLAND: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2023–2030 (USD MILLION) 258 TABLE 333 SWITZERLAND: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 258 TABLE 334 SWITZERLAND: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGICS, BY TYPE, 2023–2030 (USD MILLION) 258 TABLE 335 SWITZERLAND: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 259 TABLE 336 SWITZERLAND: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2023–2030 (USD MILLION) 259 TABLE 337 NETHERLANDS: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2023–2030 (USD MILLION) 260 TABLE 338 NETHERLANDS: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY TYPE, 2023–2030 (USD MILLION) 261 TABLE 339 NETHERLANDS: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2023–2030 (USD MILLION) 261 TABLE 340 NETHERLANDS: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 261 TABLE 341 NETHERLANDS: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGICS, BY TYPE, 2023–2030 (USD MILLION) 262 TABLE 342 NETHERLANDS: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 262 TABLE 343 NETHERLANDS: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2023–2030 (USD MILLION) 263 TABLE 344 REST OF EUROPE: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2023–2030 (USD MILLION) 264 TABLE 345 REST OF EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY TYPE, 2023–2030 (USD MILLION) 264 TABLE 346 REST OF EUROPE: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2023–2030 (USD MILLION) 265 TABLE 347 REST OF EUROPE: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 265 TABLE 348 REST OF EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGICS, BY TYPE, 2023–2030 (USD MILLION) 265 TABLE 349 REST OF EUROPE: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 266 TABLE 350 REST OF EUROPE: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2023–2030 (USD MILLION) 266 TABLE 351 ASIA PACIFIC: KEY MACROECONOMIC INDICATORS 268 TABLE 352 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 270 TABLE 353 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2023–2030 (USD MILLION) 270 TABLE 354 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY TYPE, 2023–2030 (USD MILLION) 271 TABLE 355 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2023–2030 (USD MILLION) 271 TABLE 356 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 271 TABLE 357 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGICS, BY TYPE, 2023–2030 (USD MILLION) 272 TABLE 358 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 272 TABLE 359 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2023–2030 (USD MILLION) 273 TABLE 360 CHINA: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2023–2030 (USD MILLION) 274 TABLE 361 CHINA: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY TYPE, 2023–2030 (USD MILLION) 274 TABLE 362 CHINA: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2023–2030 (USD MILLION) 275 TABLE 363 CHINA: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 275 TABLE 364 CHINA: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGICS, BY TYPE, 2023–2030 (USD MILLION) 275 TABLE 365 CHINA: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 276 TABLE 366 CHINA: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2023–2030 (USD MILLION) 276 TABLE 367 JAPAN: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2023–2030 (USD MILLION) 277 TABLE 368 JAPAN: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY TYPE, 2023–2030 (USD MILLION) 278 TABLE 369 JAPAN: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2023–2030 (USD MILLION) 278 TABLE 370 JAPAN: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 278 TABLE 371 JAPAN: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGICS, BY TYPE, 2023–2030 (USD MILLION) 279 TABLE 372 JAPAN: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 279 TABLE 373 JAPAN: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2023–2030 (USD MILLION) 280 TABLE 374 INDIA: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2023–2030 (USD MILLION) 281 TABLE 375 INDIA: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY TYPE, 2023–2030 (USD MILLION) 281 TABLE 376 INDIA: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2023–2030 (USD MILLION) 282 TABLE 377 INDIA: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 282 TABLE 378 INDIA: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGICS, BY TYPE, 2023–2030 (USD MILLION) 282 TABLE 379 INDIA: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 283 TABLE 380 INDIA: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2023–2030 (USD MILLION) 283 TABLE 381 AUSTRALIA: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2023–2030 (USD MILLION) 284 TABLE 382 AUSTRALIA: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY TYPE, 2023–2030 (USD MILLION) 285 TABLE 383 AUSTRALIA: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2023–2030 (USD MILLION) 285 TABLE 384 AUSTRALIA: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 285 TABLE 385 AUSTRALIA: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGICS, BY TYPE, 2023–2030 (USD MILLION) 286 TABLE 386 AUSTRALIA: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 286 TABLE 387 AUSTRALIA: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2023–2030 (USD MILLION) 287 TABLE 388 SOUTH KOREA: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2023–2030 (USD MILLION) 288 TABLE 389 SOUTH KOREA: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY TYPE, 2023–2030 (USD MILLION) 288 TABLE 390 SOUTH KOREA: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2023–2030 (USD MILLION) 289 TABLE 391 SOUTH KOREA: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 289 TABLE 392 SOUTH KOREA: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGICS, BY TYPE, 2023–2030 (USD MILLION) 289 TABLE 393 SOUTH KOREA: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 290 TABLE 394 SOUTH KOREA: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2023–2030 (USD MILLION) 290 TABLE 395 SINGAPORE: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2023–2030 (USD MILLION) 291 TABLE 396 SINGAPORE: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY TYPE, 2023–2030 (USD MILLION) 292 TABLE 397 SINGAPORE: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2023–2030 (USD MILLION) 292 TABLE 398 SINGAPORE: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 292 TABLE 399 SINGAPORE: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGICS, BY TYPE, 2023–2030 (USD MILLION) 293 TABLE 400 SINGAPORE: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 293 TABLE 401 SINGAPORE: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2023–2030 (USD MILLION) 294 TABLE 402 REST OF ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2023–2030 (USD MILLION) 295 TABLE 403 REST OF ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY TYPE, 2023–2030 (USD MILLION) 295 TABLE 404 REST OF ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2023–2030 (USD MILLION) 296 TABLE 405 REST OF ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 296 TABLE 406 REST OF ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGICS, BY TYPE, 2023–2030 (USD MILLION) 296 TABLE 407 REST OF ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 297 TABLE 408 REST OF ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2023–2030 (USD MILLION) 297 TABLE 409 LATIN AMERICA: KEY MACROECONOMIC INDICATORS 299 TABLE 410 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 299 TABLE 411 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2023–2030 (USD MILLION) 299 TABLE 412 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY TYPE, 2023–2030 (USD MILLION) 300 TABLE 413 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2023–2030 (USD MILLION) 300 TABLE 414 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 300 TABLE 415 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGICS, BY TYPE, 2023–2030 (USD MILLION) 301 TABLE 416 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 301 TABLE 417 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2023–2030 (USD MILLION) 302 TABLE 418 BRAZIL: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2023–2030 (USD MILLION) 303 TABLE 419 BRAZIL: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY TYPE, 2023–2030 (USD MILLION) 303 TABLE 420 BRAZIL: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2023–2030 (USD MILLION) 304 TABLE 421 BRAZIL: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 304 TABLE 422 BRAZIL: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGICS, BY TYPE, 2023–2030 (USD MILLION) 304 TABLE 423 BRAZIL: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 305 TABLE 424 BRAZIL: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2023–2030 (USD MILLION) 305 TABLE 425 MEXICO: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2023–2030 (USD MILLION) 306 TABLE 426 MEXICO: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY TYPE, 2023–2030 (USD MILLION) 307 TABLE 427 MEXICO: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2023–2030 (USD MILLION) 307 TABLE 428 MEXICO: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 307 TABLE 429 MEXICO: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGICS, BY TYPE, 2023–2030 (USD MILLION) 308 TABLE 430 MEXICO: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 308 TABLE 431 MEXICO: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2023–2030 (USD MILLION) 309 TABLE 432 REST OF LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2023–2030 (USD MILLION) 309 TABLE 433 REST OF LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY TYPE, 2023–2030 (USD MILLION) 310 TABLE 434 REST OF LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2023–2030 (USD MILLION) 310 TABLE 435 REST OF LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 310 TABLE 436 REST OF LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGICS, BY TYPE, 2023–2030 (USD MILLION) 311 TABLE 437 REST OF LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 311 TABLE 438 REST OF LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2023–2030 (USD MILLION) 312 TABLE 439 MIDDLE EAST: KEY MACROECONOMIC INDICATORS 313 TABLE 440 MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET, BY REGION, 2023–2030 (USD MILLION) 313 TABLE 441 MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2023–2030 (USD MILLION) 314 TABLE 442 MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY TYPE, 2023–2030 (USD MILLION) 314 TABLE 443 MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2023–2030 (USD MILLION) 315 TABLE 444 MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 315 TABLE 445 MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGICS, BY TYPE, 2023–2030 (USD MILLION) 315 TABLE 446 MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 316 TABLE 447 MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2023–2030 (USD MILLION) 316 TABLE 448 GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 317 TABLE 449 GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2023–2030 (USD MILLION) 317 TABLE 450 GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY TYPE, 2023–2030 (USD MILLION) 318 TABLE 451 GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2023–2030 (USD MILLION) 318 TABLE 452 GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 318 TABLE 453 GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGICS, BY TYPE, 2023–2030 (USD MILLION) 319 TABLE 454 GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 319 TABLE 455 GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2023–2030 (USD MILLION) 320 TABLE 456 SAUDI ARABIA: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2023–2030 (USD MILLION) 321 TABLE 457 SAUDI ARABIA: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY TYPE, 2023–2030 (USD MILLION) 321 TABLE 458 SAUDI ARABIA: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2023–2030 (USD MILLION) 322 TABLE 459 SAUDI ARABIA: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 322 TABLE 460 SAUDI ARABIA: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGICS, BY TYPE, 2023–2030 (USD MILLION) 322 TABLE 461 SAUDI ARABIA: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 323 TABLE 462 SAUDI ARABIA: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2023–2030 (USD MILLION) 323 TABLE 463 UAE: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2023–2030 (USD MILLION) 324 TABLE 464 UAE: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY TYPE, 2023–2030 (USD MILLION) 325 TABLE 465 UAE: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2023–2030 (USD MILLION) 325 TABLE 466 UAE: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 325 TABLE 467 UAE: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGICS, BY TYPE, 2023–2030 (USD MILLION) 326 TABLE 468 UAE: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 326 TABLE 469 UAE: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2023–2030 (USD MILLION) 327 TABLE 470 REST OF GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2023–2030 (USD MILLION) 327 TABLE 471 REST OF GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY TYPE, 2023–2030 (USD MILLION) 328 TABLE 472 REST OF GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2023–2030 (USD MILLION) 328 TABLE 473 REST OF GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 328 TABLE 474 REST OF GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGICS, BY TYPE, 2023–2030 (USD MILLION) 329 TABLE 475 REST OF GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 329 TABLE 476 REST OF GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2023–2030 (USD MILLION) 330 TABLE 477 REST OF MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2023–2030 (USD MILLION) 330 TABLE 478 REST OF MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY TYPE, 2023–2030 (USD MILLION) 331 TABLE 479 REST OF MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2023–2030 (USD MILLION) 331 TABLE 480 REST OF MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 331 TABLE 481 REST OF MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGICS, BY TYPE, 2023–2030 (USD MILLION) 332 TABLE 482 REST OF MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 332 TABLE 483 REST OF MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2023–2030 (USD MILLION) 333 TABLE 484 AFRICA: KEY MACROECONOMIC INDICATORS 334 TABLE 485 AFRICA: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2023–2030 (USD MILLION) 334 TABLE 486 AFRICA: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY TYPE, 2023–2030 (USD MILLION) 335 TABLE 487 AFRICA: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2023–2030 (USD MILLION) 335 TABLE 488 AFRICA: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 335 TABLE 489 AFRICA: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGICS, BY TYPE, 2023–2030 (USD MILLION) 336 TABLE 490 AFRICA: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 336 TABLE 491 AFRICA: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2023–2030 (USD MILLION) 337 TABLE 492 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN CLINICAL TRIAL SUPPLIES MARKET 338 TABLE 493 CLINICAL TRIAL SUPPLIES MARKET: DEGREE OF COMPETITION 342 TABLE 494 CLINICAL TRIALS SUPPLIES MARKET: REGION FOOTPRINT 346 TABLE 495 CLINICAL TRIAL SUPPLIES MARKET: SERVICE FOOTPRINT 347 TABLE 496 CLINICAL TRIAL SUPPLIES MARKET: TYPE FOOTPRINT 348 TABLE 497 CLINICAL TRIAL SUPPLIES MARKET: END-USER FOOTPRINT 349 TABLE 498 CLINICAL TRIAL SUPPLIES MARKET: DETAILED LIST OF KEY STARTUPS/SMES 351 TABLE 499 CLINICAL TRIAL SUPPLIES MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES 352 TABLE 500 CLINICAL TRIAL SUPPLIES MARKET: DEALS, JANUARY 2021–MARCH 2025 355 TABLE 501 CLINICAL TRIAL SUPPLIES MARKET: EXPANSIONS, JANUARY 2021–MARCH 2025 356 TABLE 502 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 357 TABLE 503 THERMO FISHER SCIENTIFIC INC.: SERVICES OFFERED 358 TABLE 504 THERMO FISHER SCIENTIFIC INC.: SERVICE LAUNCHES, JANUARY 2021–MARCH 2025 359 TABLE 505 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2021–MARCH 2025 359 TABLE 506 THERMO FISHER SCIENTIFIC INC.: EXPANSIONS, JANUARY 2021–MARCH 2025 360 TABLE 507 NOVO HOLDINGS A/S: COMPANY OVERVIEW 361 TABLE 508 NOVO HOLDINGS A/S: SERVICES OFFERED 362 TABLE 509 NOVO HOLDINGS A/S: DEALS, JANUARY 2021–MARCH 2025 363 TABLE 510 NOVO HOLDINGS A/S: EXPANSIONS, JANUARY 2021–MARCH 2025 364 TABLE 511 UNITED PARCEL SERVICE OF AMERICA, INC.: COMPANY OVERVIEW 366 TABLE 512 UNITED PARCEL SERVICE OF AMERICA, INC.: SERVICES OFFERED 366 TABLE 513 EUROFINS SCIENTIFIC: COMPANY OVERVIEW 369 TABLE 514 EUROFINS SCIENTIFIC: SERVICES OFFERED 370 TABLE 515 PIRAMAL PHARMA LIMITED: COMPANY OVERVIEW 372 TABLE 516 PIRAMAL PHARMA LIMITED: SERVICES OFFERED 373 TABLE 517 IQVIA: COMPANY OVERVIEW 375 TABLE 518 IQVIA: SERVICES OFFERED 377 TABLE 519 ICON PLC: COMPANY OVERVIEW 378 TABLE 520 ICON PLC: SERVICES OFFERED 379 TABLE 521 ICON PLC: DEALS, JANUARY 2021–MARCH 2025 380 TABLE 522 LONZA: COMPANY OVERVIEW 381 TABLE 523 LONZA: SERVICES OFFERED 382 TABLE 524 LONZA: DEALS, JANUARY 2021–MARCH 2025 382 TABLE 525 UNIPHAR GROUP PLC: COMPANY OVERVIEW 383 TABLE 526 UNIPHAR GROUP PLC: SERVICES OFFERED 384 TABLE 527 ALMAC GROUP: COMPANY OVERVIEW 385 TABLE 528 ALMAC GROUP: SERVICES OFFERED 385 TABLE 529 ALMAC GROUP: EXPANSIONS, JANUARY 2021–MARCH 2025 386 TABLE 530 SHARP SERVICES, LLC: COMPANY OVERVIEW 387 TABLE 531 SHARP SERVICES, LLC: SERVICES OFFERED 387 TABLE 532 PCI PHARMA SERVICES: COMPANY OVERVIEW 389 TABLE 533 PCI PHARMA SERVICES: SERVICES OFFERED 389 TABLE 534 PCI PHARMA SERVICES: EXPANSIONS, JANUARY 2021–MARCH 2025 390 TABLE 535 PAREXEL INTERNATIONAL (MA) CORPORATION: COMPANY OVERVIEW 391 TABLE 536 PAREXEL INTERNATIONAL (MA) CORPORATION.: SERVICES OFFERED 391 TABLE 537 PAREXEL INTERNATIONAL (MA) CORPORATION: DEALS, JANUARY 2021–MARCH 2025 392 TABLE 538 BIOCAIR: COMPANY OVERVIEW 393 TABLE 539 BIOCAIR: SERVICES OFFERED 393 TABLE 540 CENCORA, INC.: COMPANY OVERVIEW 394 TABLE 541 CLINIGEN LIMITED: COMPANY OVERVIEW 395 TABLE 542 KLIFO: COMPANY OVERVIEW 396 TABLE 543 IPS PHARMA: COMPANY OVERVIEW 397 TABLE 544 COREX LOGISTICS LIMITED: COMPANY OVERVIEW 398 TABLE 545 OCT GROUP LLC: COMPANY OVERVIEW 399 TABLE 546 MYONEX: COMPANY OVERVIEW 400 TABLE 547 INCEPTUA GROUP: COMPANY OVERVIEW 401 TABLE 548 ANCILLARE, LP: COMPANY OVERVIEW 402 TABLE 549 ADALLEN PHARMA: COMPANY OVERVIEW 403 TABLE 550 CLINICAL SERVICES INTERNATIONAL (CSI): COMPANY OVERVIEW 404 TABLE 551 NUVISAN GMBH: COMPANY OVERVIEW 405 TABLE 552 AENOVA HOLDING GMBH: COMPANY OVERVIEW 406 FIGURE 1 MARKET SEGMENTATION & GEOGRAPHIC SPREAD 39 FIGURE 2 CLINICAL TRIAL SUPPLIES MARKET: RESEARCH DESIGN 43 FIGURE 3 CLINICAL TRIAL SUPPLIES MARKET: BREAKDOWN OF PRIMARY INTERVIEWS 45 FIGURE 4 CLINICAL TRIAL SUPPLIES MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2024 46 FIGURE 5 CLINICAL TRIAL SUPPLIES MARKET ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2024 47 FIGURE 6 ILLUSTRATIVE EXAMPLE OF THERMO FISHER SCIENTIFIC INC.: REVENUE SHARE ANALYSIS (2024) 47 FIGURE 7 MARKET SIZE VALIDATION FROM PRIMARY SOURCES 48 FIGURE 8 SEGMENTAL MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 49 FIGURE 9 CLINICAL TRIAL SUPPLIES MARKET: CAGR PROJECTIONS 50 FIGURE 10 DATA TRIANGULATION METHODOLOGY 52 FIGURE 11 CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2025 VS. 2030 (USD MILLION) 55 FIGURE 12 CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2025 VS. 2030 (USD MILLION) 56 FIGURE 13 CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2025 VS. 2030 (USD MILLION) 57 FIGURE 14 CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2025 VS. 2030 (USD MILLION) 57 FIGURE 15 CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2025 VS. 2030 (USD MILLION) 58 FIGURE 16 GEOGRAPHIC SNAPSHOT OF CLINICAL TRIAL SUPPLIES MARKET, 2025−2030 59 FIGURE 17 GROWTH IN CLINICAL TRIALS AND DRUG DEVELOPMENT TO PROPEL MARKET 60 FIGURE 18 SMALL MOLECULES AND BIOLOGICS TO ACCOUNT FOR LARGEST MARKET SHARE IN NORTH AMERICA 61 FIGURE 19 SMALL MOLECULES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 61 FIGURE 20 CHINA PROJECTED TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD 62 FIGURE 21 CLINICAL TRIAL SUPPLIES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 64 FIGURE 22 NUMBER OF CLINICAL TRIALS PER YEAR, 2004–2024 65 FIGURE 23 CLINICAL TRIAL SUPPLIES MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 69 FIGURE 24 CLINICAL TRIAL SUPPLIES MARKET: VALUE CHAIN ANALYSIS 70 FIGURE 25 CLINICAL TRIAL SUPPLIES MARKET: ECOSYSTEM ANALYSIS 72 FIGURE 26 CLINICAL TRIAL SUPPLIES MARKET: PORTER’S FIVE FORCES ANALYSIS 86 FIGURE 27 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER 88 FIGURE 28 KEY BUYING CRITERIA FOR CLINICAL TRIAL SUPPLIES, BY END USER 89 FIGURE 29 IMPACT OF AI ON CLINICAL TRIAL SUPPLIES ECOSYSTEM 91 FIGURE 30 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET SNAPSHOT 223 FIGURE 31 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET SNAPSHOT 269 FIGURE 32 REVENUE ANALYSIS OF KEY PLAYERS IN CLINICAL TRIAL SUPPLIES MARKET, 2020–2024 (USD MILLION) 340 FIGURE 33 MARKET SHARE ANALYSIS OF KEY PLAYERS IN CLINICAL TRIAL SUPPLIES MARKET (2024) 341 FIGURE 34 CLINICAL TRIAL SUPPLIES MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024 344 FIGURE 35 CLINICAL TRIAL SUPPLIES MARKET: COMPANY FOOTPRINT 345 FIGURE 36 CLINICAL TRIAL SUPPLIES MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 350 FIGURE 37 EV/EBITDA OF KEY VENDORS 353 FIGURE 38 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 353 FIGURE 39 CLINICAL TRIAL SUPPLIES MARKET: BRAND/SERVICE COMPARATIVE ANALYSIS 354 FIGURE 40 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT 358 FIGURE 41 NOVO HOLDINGS A/S: COMPANY SNAPSHOT 362 FIGURE 42 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT 370 FIGURE 43 PIRAMAL PHARMA LIMITED: COMPANY SNAPSHOT 373 FIGURE 44 IQVIA: COMPANY SNAPSHOT 376 FIGURE 45 ICON PLC: COMPANY SNAPSHOT 378 FIGURE 46 LONZA: COMPANY SNAPSHOT 381 FIGURE 47 UNIPHAR GROUP PLC: COMPANY SNAPSHOT 383

同分類最新報告（醫療與生命科學）

查看醫療與生命科學全部報告 →

量子訊息有限公司為 MarketsandMarkets 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們